Rasio rega marang prakiraan pendapatan viracta.com (VIRX)
The forward P/S trajectory demonstrates the potential of the precision activator IT platform against lymphomas, where is the current level of the metric for Viracta Therapeutics (VIRX). Business efficiency relies on the "Kick and Kill" method for the targeted destruction of tumors associated with the Epstein-Barr virus. A stable staff of epigenetics experts and the hiring of data analysts guarantee the achievement of key clinical goals.
Rincian analitis perusahaan Viracta Therapeutics, Inc. (VIRX)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- informasi babagan utang lan solvabilitas:
Rasio Total Utang marang Ekuitas Viracta Therapeutics|VIRX - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang modal Viracta Therapeutics Inc.|VIRX - Gunggung utang perusahaan|Utang marang nilai buku Viracta Therapeutics Inc.|VIRX - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Viracta Therapeutics|Rasio cepet viracta.com
- rincian asil keuangan lan kelipatan valuasi:
VIRX - Bathi pungkasan|Proyeksi bathi mangsa ngarep Viracta Therapeutics|VIRX - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Viracta Therapeutics|VIRX - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Viracta Therapeutics|VIRX - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Viracta Therapeutics|VIRX - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan viracta.com|VIRX - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Viracta Therapeutics
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Viracta Therapeutics, Inc. (VIRX)
For Viracta Therapeutics (VIRX), which is developing an innovative "kick and kill" strategy in cancer therapy, the forward P/S ratio reflects market expectations for the future commercialization of its drugs. This metric correlates current market capitalization with projected revenue per share, allowing investors to assess the premium paid for potential growth and timely revise capital concentration risks when the indicator reaches extreme values.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake xiliotx.com (XLO)|Renovaro - Multiplikator Forward P/S|Mural Oncology (MURA) - Multiplikator forward rega marang pendapatan|KAPA: Multiplikator Forward P/S|OKUR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Limited|CRIS: Rega forward marang dodolan|Multiplikator Forward P/S APLM|Multiplikator Forward P/S tharimmune.com (THAR)|Advanced Biomed Corp - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GNPX|Calidi Biotherapeutics, Inc. - Multiplikator Forward P/S|Sunshine Biopharma (SBFM) - Multiplikator forward rega marang pendapatan|XBIO: Multiplikator Forward P/S|SLRX - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PPBT|Multiplikator Forward P/S American Oncology Network|Rasio rega marang prakiraan pendapatan BeOne Medicines (BGNE)|CKPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ELEV (Elevation Oncology Inc.)|Multiplikator Forward P/S iCAD Corp ICAD|Ikena - Multiplikator Forward P/S|Rega forward marang dodolan NTBL (Notable Labs)|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S
